The introduction of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) monoclonal antibodies either alone or in combination with chemotherapy has changed the first-line treatment landscape of patients with advanced NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.